Biotech | November 02, 2021
AstraZeneca to transfer global rights for Eklira and Duaklir to Covis Pharma
The agreement sharpens the company’s focus on priority medicines in respiratory & immunology portfolio
The agreement sharpens the company’s focus on priority medicines in respiratory & immunology portfolio
The collaboration aims to deliver greater insights to the oncology fraternity, predict patient therapy responses and enable therapy selection resulting in optimal treatment outcomes.
Dupixent is the only biologic medicine to improve lung function in children aged 6 to 11 years in a randomized Phase 3 trial, supporting potential as a best-in-class option
The new products include the COAG Line automated, semi-automated and POC systems manufactured by Diagon Hungary
CuraTeQ Biologics is on track for filing a second oncology biosimilar
The study is being carried out by the platform VISION (Vaccine Immunology Studies – Indian Outbreak-response Network) which includes top public and private research institutes.
Researchers at the Feinstein Institutes administer extra vaccine doses as part of the NIH funded study
JADE DARE trial met co-primary and key secondary endpoints and demonstrated a safety profile consistent with previous studies for moderate to severe atopic dermatitis
Textiles treated with the technology have also been proven to deactivate viruses, including SARS-CoV-2 (the virus that causes COVID-19).
XELJANZ is the first and only Janus kinase (JAK) inhibitor approved in Europe for the treatment of polyarticular JIA and juvenile PsA and has received regulatory approval in four indications in the European Union, the most of any JAK inhibitor
Subscribe To Our Newsletter & Stay Updated
